These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 17906326)
1. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Tonelli M; Wiebe N; Culleton B; Lee H; Klarenbach S; Shrive F; Manns B; Nephrol Dial Transplant; 2007 Oct; 22(10):2856-66. PubMed ID: 17906326 [TBL] [Abstract][Full Text] [Related]
2. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. Patel L; Bernard LM; Elder GJ Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024 [TBL] [Abstract][Full Text] [Related]
3. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials. Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157 [TBL] [Abstract][Full Text] [Related]
4. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE; Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079 [TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467 [TBL] [Abstract][Full Text] [Related]
6. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study. Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017 [TBL] [Abstract][Full Text] [Related]
7. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Sprague SM Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307 [TBL] [Abstract][Full Text] [Related]
8. Initiation of Sevelamer and Mortality among Hemodialysis Patients Treated with Calcium-Based Phosphate Binders. Komaba H; Wang M; Taniguchi M; Yamamoto S; Nomura T; Schaubel DE; Smith AR; Zee J; Karaboyas A; Bieber B; Fukagawa M; Tentori F Clin J Am Soc Nephrol; 2017 Sep; 12(9):1489-1497. PubMed ID: 28724618 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective. Vegter S; Tolley K; Keith MS; Lok CE; Soroka SD; Morton AR Clin Ther; 2012 Jul; 34(7):1531-43. PubMed ID: 22742885 [TBL] [Abstract][Full Text] [Related]
10. Ten-year experience with sevelamer and calcium salts as phosphate binders. Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501 [TBL] [Abstract][Full Text] [Related]
11. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. St Peter WL; Liu J; Weinhandl E; Fan Q Am J Kidney Dis; 2008 Mar; 51(3):445-54. PubMed ID: 18295060 [TBL] [Abstract][Full Text] [Related]
12. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Goldsmith DR; Scott LJ; Cvetković RS; Plosker GL Drugs; 2008; 68(1):85-104. PubMed ID: 18081374 [TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S; Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402 [TBL] [Abstract][Full Text] [Related]
14. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients. Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903 [TBL] [Abstract][Full Text] [Related]
15. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer? Negri AL J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415 [TBL] [Abstract][Full Text] [Related]
16. The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials. Liu L; Wang Y; Chen H; Zhu X; Zhou L; Yang Y Ren Fail; 2014 Sep; 36(8):1244-52. PubMed ID: 25019348 [TBL] [Abstract][Full Text] [Related]
17. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Di Iorio B; Bellasi A; Russo D; Clin J Am Soc Nephrol; 2012 Mar; 7(3):487-93. PubMed ID: 22241819 [TBL] [Abstract][Full Text] [Related]
18. Effect of gastric acid suppression with pantoprazole on the efficacy of sevelamer hydrochloride as a phosphate binder in haemodialysis patients: a pilot study. Lai B; Cervelli MJ Nephrology (Carlton); 2012 May; 17(4):402-6. PubMed ID: 22329674 [TBL] [Abstract][Full Text] [Related]
19. Effects and safety of iron-based phosphate binders in dialysis patients: a systematic review and meta-analysis. Zhai CJ; Yu XS; Yang XW; Sun J; Wang R Ren Fail; 2015 Feb; 37(1):7-15. PubMed ID: 25350834 [TBL] [Abstract][Full Text] [Related]
20. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]